RARE
Ultragenyx Pharmaceutical Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Did you know?
Trading 14% below its estimated fair value of $28.14.
Current Price
$24.77
+0.32%GoodMoat Value
$28.14
13.6% undervaluedProfile
Valuation (TTM)
Market Cap$2.39B
P/E-4.16
EV—
P/B—
Shares Out96.48M
P/Sales3.55
Revenue$673.00M
EV/EBITDA—
Ultragenyx Pharmaceutical Inc (RARE) Stock Analysis
Market Cap$2.39B
Current Price$24.77
P/E Ratio-4.16
Forward P/E—
PEG Ratio0.57
EPS$-5.83
Book Value$-0.90
P/B Ratio—
RARE Financial Charts
RARE 52-Week Range
$18.50
$41.44
50-Day MA: $22.55200-Day MA: $27.72
Did you know?
Trading 14% below its estimated fair value of $28.14.
Ultragenyx Pharmaceutical Inc (RARE) Financial Summary
Ultragenyx Pharmaceutical Inc (RARE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $24.77 with a market capitalization of $2.39B.
Key valuation metrics include a P/E ratio of -4.16, and EPS of $-5.83. The company reports a profit margin of -85.4%.
RARE Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $2.39B |
| P/E Ratio | -4.16 |
| EPS | $-5.83 |
| P/S Ratio | 3.55 |
| Profit Margin | -85.4% |
Ultragenyx Pharmaceutical Inc (RARE) Valuation
Based on GoodMoat's DCF model, Ultragenyx Pharmaceutical Inc has a fair value estimate of $28.14. At the current price of $24.77, the stock appears 12.0% undervalued relative to our intrinsic value estimate.
RARE Quality Indicators
Ultragenyx Pharmaceutical Inc maintains a profit margin of -85.4% and an operating margin of -79.5%. The current ratio is 2.48.
About Ultragenyx Pharmaceutical Inc
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
RARE Free Cash Flow
Ultragenyx Pharmaceutical Inc generated $-472.00M in trailing twelve-month free cash flow, representing an FCF yield of -19.75%. This low FCF yield may reflect heavy reinvestment or growth spending.
RARE Shares Outstanding
Ultragenyx Pharmaceutical Inc has 0.10 billion shares outstanding at a share price of $24.77, giving it a market capitalization of $2.39B.